Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Greil

Showing results (261-270 of 483) with videos related to

Pageof 49
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 9, 2019
Prediction of Distant Recurrence Using EndoPredict Among Women with ER<sup>+</sup>, HER2<sup>-</sup> Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy OnlyMartin Filipits, Peter Dubsky, Margaretha Rudas, et al.
Breast Cancer Research and Treatment|December 26, 2007
Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17)Brigitte Mlineritsch, Christoph Tausch, Christian Singer, et al.
Blood|June 11, 2021
CD44 loss of function sensitizes AML cells to the BCL-2 inhibitor venetoclax by decreasing CXCL12-driven survival cuesXiaobing Yu, Leonel Munoz-Sagredo, Karolin Streule, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2011
Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancerZsuzsanna Bago-Horvath, Margaretha Rudas, Peter Dubsky, et al.
Scientific Reports|August 14, 2025
C to U RNA editing of MFN1 is regulated by ADARB1 and associates with favourable prognosis in chronic lymphocytic leukemiaAlejandra Gonzalez Martinez, Franz Josef Gassner, Dominik Baumgartner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2008
Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapyMargaretha Rudas, Martina Lehnert, Anh Huynh, et al.
The Lancet. Oncology|January 15, 2013
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trialIstvan Lang, Thomas Brodowicz, Larisa Ryvo, et al.
Cancer Research|March 19, 2009
Circulating B-cell chronic lymphocytic leukemia cells display impaired migration to lymph nodes and bone marrowTanja Nicole Hartmann, Valentin Grabovsky, Wei Wang, et al.
Haematologica|April 19, 2012
Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical responseUlrich Jäger, Michael Fridrik, Markus Zeitlinger, et al.
Molecular Oncology|July 3, 2020
Epidermal activation of Hedgehog signaling establishes an immunosuppressive microenvironment in basal cell carcinoma by modulating skin immunitySandra Grund-Gröschke, Daniela Ortner, Antal B Szenes-Nagy, et al.
Pageof 49

Showing results (261-270 of 483) with videos related to

Sort By:
Pageof 49
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 9, 2019
Prediction of Distant Recurrence Using EndoPredict Among Women with ER<sup>+</sup>, HER2<sup>-</sup> Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy OnlyMartin Filipits, Peter Dubsky, Margaretha Rudas, et al.
Breast Cancer Research and Treatment|December 26, 2007
Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17)Brigitte Mlineritsch, Christoph Tausch, Christian Singer, et al.
Blood|June 11, 2021
CD44 loss of function sensitizes AML cells to the BCL-2 inhibitor venetoclax by decreasing CXCL12-driven survival cuesXiaobing Yu, Leonel Munoz-Sagredo, Karolin Streule, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2011
Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancerZsuzsanna Bago-Horvath, Margaretha Rudas, Peter Dubsky, et al.
Scientific Reports|August 14, 2025
C to U RNA editing of MFN1 is regulated by ADARB1 and associates with favourable prognosis in chronic lymphocytic leukemiaAlejandra Gonzalez Martinez, Franz Josef Gassner, Dominik Baumgartner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2008
Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapyMargaretha Rudas, Martina Lehnert, Anh Huynh, et al.
The Lancet. Oncology|January 15, 2013
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trialIstvan Lang, Thomas Brodowicz, Larisa Ryvo, et al.
Cancer Research|March 19, 2009
Circulating B-cell chronic lymphocytic leukemia cells display impaired migration to lymph nodes and bone marrowTanja Nicole Hartmann, Valentin Grabovsky, Wei Wang, et al.
Haematologica|April 19, 2012
Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical responseUlrich Jäger, Michael Fridrik, Markus Zeitlinger, et al.
Molecular Oncology|July 3, 2020
Epidermal activation of Hedgehog signaling establishes an immunosuppressive microenvironment in basal cell carcinoma by modulating skin immunitySandra Grund-Gröschke, Daniela Ortner, Antal B Szenes-Nagy, et al.
Pageof 49